selected scholarly activity
-
chapters
-
conferences
- ANATOMY OF STROKE CARE IN UGANDA'S TERTIARY HOSPITALS: ORGANIZED STROKE CARE ACROSS INCOME LEVELS (OSCAIL) STUDY. International Journal of Stroke. 743-743. 2020
- BARRIERS AND FACILITATORS TO IMPLEMENTING ORGANIZED STROKE CARE IN INDIA: RESULTS FROM INDIA OF THE ORGANIZED STROKE CARE ACROSS INCOME LEVELS (OSCAIL STUDY). International Journal of Stroke. 329-329. 2020
- CAN STROKE UNIT CARE BE IMPLEMENTED IN UNDER-RESOURCED SETTINGS IN RWANDA? RESULTS FROM THE ORGANIZED STROKE CARE ACROSS INCOME LEVELS (OSCAIL) STUDY. International Journal of Stroke. 19-19. 2020
- Efficacy and safety of low-dose rivaroxaban on top of aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. European Heart Journal. 1449-1449. 2020
- IMPLEMENTING KEY ASPECTS OF STROKE CARE IN LOW-RESOURCE SETTINGS: RESULTS OF THE OSCAIL STUDY. International Journal of Stroke. 742-742. 2020
- OSACIL STUDY: SEX, ACCESS TO STROKE SERVICES, AND MORTALITY IN LOW-RESOURCE SETTINGS. International Journal of Stroke. 747-747. 2020
- OSCAIL STUDY: IMPROVING ACUTE STROKE SERVICES IN SOUTH AFRICA. International Journal of Stroke. 744-744. 2020
- Understanding the Black Box of Intensive Care Unit Rehabilitation Interventions with Mechanically Ventilated Patients: A Review of 87 Prospective Studies. American Journal of Respiratory and Critical Care Medicine. 2020
- Legacy of Lipid Lowering in Preventing Fatal and Non Fatal Cardiovascular Events in Individuals Without Cardiovascular Disease During 3 Years of Post Trial Observation in the HOPE 3 (Heart Outcomes Prevention Evaluation) Study. Circulation Research. E108-E108. 2019
- Legacy of Lipid Lowering in Preventing Fatal and Non Fatal Cardiovascular Events in Individuals Without Cardiovascular Disease During 3 Years of Post -Trial Observation in the Hope 3 (Heart Outcomes Prevention Evaluation 3) Study. Circulation. 2019
- Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. European Heart Journal. 1274-1274. 2019
- Risk factors and clinical outcomes in chronic CAD and PAD: an analysis of the randomized, double-blind COMPASS trial. European Heart Journal. 2472-2472. 2019
- Angiotensin-converting enzyme and type 2 diabetes risk: a Mendelian randomisation study. Diabetologia. S108-S108. 2019
- 240-LB: Angiotensin-Converting Enzyme and Type 2 Diabetes Risk: A Mendelian Randomization Study. Diabetes. 2019
- A RANDOMIZED TRIAL OF PROTON PUMP INHIBITORS VERSUS PLACEBO TO PREVENT UPPER GASTROINTESTINAL BLEEDING IN PATIENTS RECEIVING RIVAROXABAN OR ASPIRIN. Gastroenterology. S174-S174. 2019
- ADVERSE EVENTS RELATED TO PROTON PUMP INHIBITOR THERAPY. RESULTS OF A RANDOMIZED TRIAL OF PANTOPRAZOLE VERSUS PLACEBO WITH 53,152 PATIENT YEARS OF FOLLOW-UP. Gastroenterology. S173-S174. 2019
- Effect of Oral Factor Xa Inhibitors on the Risk of Subdural Hematoma: COMPASS trial Results and Systematic Review. Stroke. 2019
- CAN KEY ELEMENTS OF A STROKE UNIT BE IMPLEMENTED IN RESOURCE SCARCE SETTINGS? WHERE DO WE START ( THE OSCAIL STUDY). International Journal of Stroke. 74-74. 2018
- CHARACTERIZATION OF STROKES ADMITTED TO KALAFONG HOSPITAL, PRETORIA, SOUTH AFRICA DURING THE BASELINE PHASE OF THE OSCAIL STUDY. International Journal of Stroke. 202-202. 2018
- DATA FROM THE OSCAIL STUDY ON TIME FROM STROKE ONSET TO PRESENTATION AT 3 PUBLIC AFRICAN HOSPITALS: TWO IN RWANDA AND ONE IN SOUTH AFRICA. International Journal of Stroke. 201-201. 2018
- DEVELOPING REHABILITATION SPECIFIC TRAINING FOR ORGANIZED STROKE CARE IN LOW AND MIDDLE INCOME COUNTRIES: WHAT IS NEEDED AND HOW TO IMPLEMENT. International Journal of Stroke. 41-41. 2018
- MOBILITY-RELATED CARE AFTER STROKE IN THE RWANDAN AND SOUTH AFRICAN CONTEXT: IDENTIFYING OPPORTUNITIES FOR IMPROVEMENT THROUGH THE ORGANIZED STROKE CARE ACROSS INCOME LEVELS (OSCAIL) STUDY. International Journal of Stroke. 114-114. 2018
- THE EFFECT OF LOSS TO FOLLOW-UP ON ESTIMATING POST-STROKE FUNCTION AND MORTALITY IN LOW AND MIDDLE-INCOME COUNTRIES: LESSONS FROM THE OSCAIL STUDY. International Journal of Stroke. 110-110. 2018
- THE EFFECTIVENESS OF SUPPORT AND TRAINING FOR SETTING UP ORGANIZED STROKE CARE PATHWAYS IN IMPROVING THE CLINICAL OUTCOME FOLLOWING A STROKE (OSCAIL). International Journal of Stroke. 164-164. 2018
- THE OSCAIL STUDY: MONITORING ACUTE STROKE CARE SERVICES IN RWANDA AND SOUTH AFRICA. International Journal of Stroke. 194-194. 2018
- THERAPISTS' UNDERSTANDING OF THE CANADIAN BEST PRACTICE RECOMMENDATIONS FOR UPPER EXTREMITY REHABILITATION AFTER STROKE; AND BARRIERS AND FACILITATORS FOR THEIR IMPLEMENTATION. International Journal of Stroke. 170-170. 2018
- First Stroke Reduced 44 Percent by Well Tolerated Medications. Stroke Outcomes From the Heart Outcomes Prevention Evaluation 3 Study. Stroke. 2018
- Costs Impact Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial. Circulation. E456-E457. 2017
- Impact of Rivaroxaban Alone or in Combination With Aspirin versus Aspirin in Preventing Graft Occlusion in Patients With CABG Surgery COMPASS CABG. Circulation. 2017
- Marked Global Variability in Cost Effectiveness of Lipid-Lowering and Combination Antihypertensive Therapies in Primary Prevention: Analyses of the HOPE-3 Trial. Circulation. 2017
- Predictors of cognitive decline after cardiac surgery: an evaluation of the CABG off or on pump revascularization study (CORONARY) cohort. European Heart Journal. 445-446. 2017
- The Effect of Blood Pressure and Cholesterol Lowering on Cognition. Circulation. E703-E704. 2016
- [PP.26.05] BLOOD PRESSURE LOWERING IN INTERMEDIATE RISK PEOPLE WITHOUT VASCULAR DISEASE. Journal of Hypertension. e274-e275. 2016
- Initiative to streamline clinical trials (ISCT): Guidance for academic investigators/sponsors.. Journal of Clinical Oncology. 219-219. 2016
- Frequency of Intracranial Arterial Imaging and its Yield in Consecutive Patients with Non-lacunar Cryptogenic Ischemic Stroke: ESUS Global Registry. Stroke. 2016
- Most patients in stroke rehab are not eligible for independent walking interventions: Lessons from the IMPACT walking study. International Journal of Stroke. 7-7. 2015
- Prevalence of potential minor risk sources of embolism in patients with embolic stroke of undetermined source (ESUS) - A global survey. International Journal of Stroke. 12-12. 2015
- Global survey of the frequency of AF-associated stroke and its detection. International Journal of Stroke. 267-267. 2015
- Frequency Aad Features of Patients With Embolic Strokes of Underdetermined Source (esus): Esus Global Registry. Stroke. 2015
- Frequency and Features of Patients with Embolic Stroke of Undetermined Source(ESUS). Stroke. E267-E268. 2014
- Global Survey of the Diagnostic Evaluation and Management of Cryptogenic Ischemic Stroke. Stroke. E280-E281. 2014
- What About the Other 12 Hours? Development and Pilot Testing of a Novel Program to Increase Walking-Related Practice During Stroke Rehabilitation. Stroke. E286-E286. 2014
- Effects of Insulin Glargine on Left Ventricular Mass and Function in Patients With Dysglycemia. Circulation. 2014
- Outcome reduction with an initial glargine intervention and legacy effects (ORIGINALE). Diabetologia. S516-S516. 2014
- Effects of n-3 fatty acids on long-term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. European Heart Journal. 352-352. 2013
- Cancer Outcomes in Patients With Dysglycemia on Basal Insulin: Results of the ORIGIN Trial. Diabetes. A98-A98. 2013
- Cancer Outcomes in Patients With Dysglycemia on Basal Insulin: Results of the ORIGIN Trial. Diabetes. A72-A72. 2013
- Effect of Basal Insulin Glargine and Omega 3 FA on Cognitive Decline and Dementia in People With Dysglycemia. Diabetes. A308-A308. 2013
- Handgrip Strength Is Associated With Glomerular Filtration Rate in Patients With Diabetes Type 2. Diabetes. A393-A393. 2013
- Handgrip Strength Predicts Cardiovascular Mortality: A Subanalysis of the ORIGIN Trial. Diabetes. A367-A367. 2013
- Incident cancers in people with dysglycemia and other cardiovascular risk factors: Cohort study of the ORIGIN trial.. Journal of Clinical Oncology. 1504-1504. 2011
- Development of the Self-management and Task-oriented Approach to Rehabilitation Training (START) at home: a knowledge translation study. Stroke. E505-E505. 2010
- 55 HEMODYNAMIC EFFECTS AND SAFETY OF ONE-MONTH SIMVASTATIN TREATMENT IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER TRIAL. Journal of Hepatology. S25-S25. 2008
- Glucose levels predict incident cardiovascular events in a large international multiethnic cohort. Circulation. 835-835. 2007
- Obesity metrics and their associations with type 2 diabetes and glucose levels in a large international multi-ethnic cohort. Circulation. 318-319. 2007
- Design and baseline characteristics of the DREAM (diabetes REduction assessment with ramipril and rosiglitazone medication) trial. Diabetes. A483-A483. 2004
- Beneficial effects of ramipril on cardiovascular events in high-risk patients older than 75 years of age: Secondary outcomes from the HOPE trial. Journal of the American College of Cardiology. 154-154. 2003
- Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk diabetic patients. Journal of the American College of Cardiology. 291-291. 2002
- Ramipril prevents major cardiovascular events in high-risk women: results of the HOPE trial. Journal of the American College of Cardiology. 290-291. 2002
- Impact of abdominal obesity on the occurrence of diabetes in subjects with ischemic cardiovascular disease. Circulation. 833-833. 2001
- Effects of ramipril on left ventricular mass and function in normotensive, high-risk patients with normal ejection fraction. A substudy of HOPE. Journal of the American College of Cardiology. 165A-165A. 2001
- Effects of ramipril on the incidence of myocardial infarction in high risk patients: The HOPE Study. Circulation. 705-705. 2000
- Renal insufficiency as a predictor of cardiovascular outcomes and impact of ramipril: The HOPE study. Circulation. 655-655. 2000
- Abdominal adiposity as a prognostic factor for persons at high risk of cardiovascular events. Journal of the American College of Cardiology. 284A-284A. 2000
- Impact of Ramipril and vitamin A on cerebrovascular events in the HOPE (Heart outcomes prevention evaluation) trial. Journal of the American College of Cardiology. 324A-324A. 2000
- Left ventricular hypertrophy predicts death and development of heart failure in high risk patients without systolic dysfunction. Journal of the American College of Cardiology. 212A-212A. 2000
- Prevention of heart failure by Ramipril in high risk patients without heart failure or systolic dysfunction. Journal of the American College of Cardiology. 203A-203A. 2000
- Ramipril prevents cardiovascular events in high risk diabetic participants: Results of the HOPE study. Journal of the American College of Cardiology. 301A-301A. 2000
- Results of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 185-185. 1999
- Albuminuria is highly prevalent and predicts cardiovascular events in high risk diabetic and nondiabetic patients. Circulation. 1245-1245. 1997
- Is there a gender bias in the cardiovascular drug treatment of high-risk women?. Circulation. 143-143. 1997
- Left ventricular hypertrophy is a potent independent risk factor for adverse cardiovascular outcomes. Circulation. 2600-2600. 1997
- PROPRANOLOL IN THE PREVENTION OF REBLEEDING FROM PORTAL HYPERTENSIVE GASTROPATHY - A MULTICENTER RANDOMIZED CONTROLLED TRIAL. Hepatology. 870-870. 1990
- HEMODYNAMIC EVENTS IN A PROSPECTIVE RANDOMIZED TRIAL OF PROPRANOLOL VS PLACEBO IN THE PREVENTION OF THE 1ST VARICEAL HEMORRHAGE. Hepatology. 1242-1242. 1988
- PROPRANOLOL IN THE PREVENTION OF 1ST HEMORRHAGE FROM ESOPHAGEAL-VARICES (EVH) - A MULTICENTER CONTROLLED TRIAL. Hepatology. 1220-1220. 1988
-
journal articles
- Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. The Lancet Diabetes and Endocrinology. 12:306-319. 2024
- The Effects of Pantoprazole on Kidney Outcomes. Journal of the American Society of Nephrology. 2024
-
Effect of basal insulin and omega 3 fatty acids on cognitive impairment in dysglycaemia: An exploratory analysis of the
ORIGIN trial. Diabetes, Obesity and Metabolism. 26:1180-1187. 2024 - Global stroke statistics 2023: Availability of reperfusion services around the world. International Journal of Stroke. 19:253-270. 2024
- Identifying the highest risk vascular patients: Insights from the XATOA registry. American Heart Journal. 269:191-200. 2024
- The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective. American Journal of Cardiovascular Drugs. 24:117-127. 2024
- Cognitive performance following stroke, transient ischaemic attack, myocardial infarction, and hospitalisation: an individual participant data meta-analysis of six randomised controlled trials. The Lancet Healthy Longevity. 4:e665-e674. 2023
- Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials. Lancet Neurology. 22:1140-1149. 2023
- Antiplatelet therapy and incident cognitive impairment or dementia—a systematic review and meta-analysis of randomised clinical trials. Age and Ageing. 52:afad197. 2023
- Assessing Limb Outcomes in Drug Trials in Peripheral Artery Disease: The Need for a Universal and Pragmatic Definition. European Journal of Vascular and Endovascular Surgery. 66:442-443. 2023
- The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial. European Heart Journal - Quality of Care and Clinical Outcomes. 9:502-510. 2023
- Effectiveness of interventions by non-professional community-level workers or family caregivers to improve outcomes for physical impairments or disabilities in low resource settings: systematic review of task-sharing strategies. Human Resources for Health. 21:48. 2023
- Strategies for specialty training of healthcare professionals in low-resource settings: a systematic review on evidence from stroke care. BMC Medical Education. 23:442. 2023
- Dietary intake and cardiovascular outcomes in patients with chronic vascular disease: insights from the COMPASS trial cohort. European Journal of Preventive Cardiology (EJPC). 30:709-718. 2023
- Health status and cognitive function for risk stratification in chronic coronary and peripheral artery disease. European Journal of Preventive Cardiology (EJPC). 30:535-545. 2023
- Comparator Groups in ICU-Based Studies of Physical Rehabilitation: A Scoping Review of 125 Studies. Critical Care Explorations. 5:e0917-e0917. 2023
- The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial. Atherosclerosis. 372:41-47. 2023
- A hybrid automated event adjudication system for clinical trials. Clinical Trials. 20:166-175. 2023
- Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial. American Heart Journal. 258:60-68. 2023
- Does GERAS DANCE improve gait in older adults?. Aging and Health Research. 3:100120-100120. 2023
- Vitamin D supplementation and adverse skeletal and non-skeletal outcomes in individuals at increased cardiovascular risk: Results from the International Polycap Study (TIPS)-3 randomized controlled trial. Nutrition, Metabolism and Cardiovascular Diseases. 33:434-440. 2023
- Impact of Rabeprazole on APO-Dabigatran Exposure in Healthy Volunteers. CJC OPEN. 5:1-7. 2023
- World-wide variations in tests of cognition and activities of daily living in participants of six international randomized controlled trials. Cerebral Circulation - Cognition and Behavior. 5:100176-100176. 2023
- Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 8:825-836. 2022
- Are clinical trials randomising households to lifestyle interventions to delay cognitive decline feasible? A pilot study to determine the beliefs, preferences, and deterrents for households impacted by dementia based on semi-structured interviews. BMC Geriatrics. 22:322. 2022
- Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. The Lancet Respiratory Medicine. 10:1160-1168. 2022
- Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. The Lancet Respiratory Medicine. 10:1169-1177. 2022
- Retention in RCTs of physical rehabilitation for adults with frailty: a systematic review and meta-analysis. Trials. 23:235. 2022
- Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events. JAMA network open. 5:e2243201-e2243201. 2022
- INTERBLEED: Design of an International Study of Risk Factors for Gastrointestinal Bleeding and Cardiovascular Events After Gastrointestinal Bleeding. CJC OPEN. 4:996-1005. 2022
- Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. European Heart Journal. 43:3542-3552. 2022
- Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. The Lancet. 400:832-845. 2022
- Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 8:462-473. 2022
- Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. Circulation. 145:1875-1877. 2022
- Impact of Bioelectrical Impedance–Guided Fluid Management and Vitamin D Supplementation on Left Ventricular Mass in Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial. American Journal of Kidney Diseases. 79:820-831. 2022
- The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges. CJC OPEN. 4:568-576. 2022
- Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial. Journal of Stroke and Cerebrovascular Diseases. 31:106404-106404. 2022
- Systematic review: patient-reported outcome measures of fatigue in inflammatory bowel disease. Fatigue: Biomedicine, Health and Behavior. 10:60-82. 2022
- Functional Abilities of an International Post-Stroke Population: Standard Assessment of Global Everyday Activities (SAGEA) Scale. Journal of Stroke and Cerebrovascular Diseases. 31:106329-106329. 2022
- FUNCTIONAL OUTCOMES OF INDIVIDUALS WITH CARDIOVASCULAR DISEASE AFTER GASTROINTESTINAL CANCER. Journal of Cancer Rehabilitation. 5:48-55. 2022
- Provision and use of physical rehabilitation services for adults with disabilities in Rwanda: A descriptive study. African Journal of Disability. 11:1004. 2022
- Standardized Assessment of Global activities in the Elderly scale in adult cardiac surgery patients. British Journal of Anaesthesia. 127:539-546. 2021
- Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. The Lancet. 398:1133-1146. 2021
- Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. European Heart Journal. 42:2995-3007. 2021
- Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke. 52:2494-2501. 2021
- Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Heart. 107:1130-1137. 2021
- Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. Journal of the American College of Cardiology. 78:14-23. 2021
- The Relationship Between Glucose Control and Cognitive Function in People With Diabetes After a Lacunar Stroke. Journal of Clinical Endocrinology and Metabolism (JCEM). 106:1521-1528. 2021
- Recognising HIV infection in systems of care for stroke – Authors' reply. The Lancet. 397:794-795. 2021
- Polypill with or without Aspirin in Persons without Cardiovascular Disease. New England Journal of Medicine. 384:216-228. 2021
- Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. Cardioscience. 117:576-584. 2021
- Feasibility of studying the association between intraoperative regional cerebral oxygen saturation and postoperative functional decline (ReFUNCTION): a pilot sub-study of NeuroVISION-Cardiac Surgery. Canadian Journal of Anaesthesia. 67:1497-1506. 2020
- Promoting Independent Mobility-related Physical ACTivity (IMPACT) in an inpatient stroke rehabilitation unit: a proof-of-concept evaluation of self-management intervention. Disability and Rehabilitation. 42:3172-3181. 2020
- Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. Stroke. 51:2901-2909. 2020
- Stroke systems of care in low-income and middle-income countries: challenges and opportunities. The Lancet. 396:1443-1451. 2020
- Oral factor Xa inhibitors and risk of subdural hematoma. Neurology. 95:e480-e487. 2020
- Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. Circulation. 141:1841-1854. 2020
- Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment. Journal of the American Medical Association (JAMA). 323:1934-1934. 2020
- Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation. 141:1141-1151. 2020
- ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study. Diabetes Reviews. 43:835-842. 2020
- Are large simple trials for dementia prevention possible?. Age and Ageing. 49:154-160. 2020
- Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. European Journal of Preventive Cardiology (EJPC). 27:296-307. 2020
- Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes. JAMA Neurology. 77:43-43. 2020
- Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. European Heart Journal. 40:3771-3778a. 2019
- Can occupational therapists integrate new evidence into guideline-informed practice? They can, they do, and you can too. Occupational Therapy Now. 21:9-11. 2019
- Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. Circulation. 140:1451-1459. 2019
- Cross-cultural adaptation and psychometric evaluation of the Singapore version of the Chedoke Arm and Hand Activity. Disability and Rehabilitation. 41:2570-2577. 2019
- Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. Journal of the American College of Cardiology. 74:1519-1528. 2019
- Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. Circulation. 140:529-537. 2019
- Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology. 157:403-412.e5. 2019
- Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. Journal of the American College of Cardiology. 73:3271-3280. 2019
- The cost implication of primary prevention in the HOPE 3 trial. European Heart Journal - Quality of Care and Clinical Outcomes. 5:266-271. 2019
- Effects of basal insulin glargine and omega‐3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial. Diabetes, Obesity and Metabolism. 21:1502-1505. 2019
- Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?. European Heart Journal. 40:1466-1471. 2019
- Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study. European Journal of Preventive Cardiology (EJPC). 26:681-697. 2019
- Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. Thrombosis and Haemostasis. 119:576-585. 2019
- Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. International Journal of Stroke. 14:270-281. 2019
- Effects of blood pressure and lipid lowering on cognition. Neurology. 92:e1435-e1446. 2019
- Stroke Outcomes in the COMPASS Trial. Circulation. 139:1134-1145. 2019
- Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial. Diabetes Reviews. 42:142-147. 2019
- Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. Journal of the American College of Cardiology. 73:121-130. 2019
- Comparison of the sensitivity to change of the Functional Independence Measure with the Assessment of Motor and Process Skills within different rehabilitation populations. Disability and Rehabilitation. 40:3177-3184. 2018
- Reliability and validity of the shortened Singapore versions of the Chedoke Arm and Hand Activity Inventory. International Journal of Rehabilitation Research. 41:297-303. 2018
- The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct. American Heart Journal. 206:72-79. 2018
- Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease (vol 374, pg 2032, 2016). New England Journal of Medicine. 379:1486-1486. 2018
- Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada. Journal of Thrombosis and Thrombolysis. 46:310-315. 2018
- Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry. European Urology Focus. 4:694-701. 2018
- Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial. Journal of the American Heart Association. 7:e008918. 2018
- Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology. 71:2306-2315. 2018
- Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. JAMA cardiology. 3:225-225. 2018
- External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. European Heart Journal. 39:750-757a. 2018
- Identifying and Treating Young Patients at Risk for Cardiovascular Events. Journal of the American College of Cardiology. 71:303-305. 2018
- Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial. Canadian Journal of Cardiology. 34:38-44. 2018
- Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). Journal of the National Cancer Institute. 110:40-48. 2018
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 391:205-218. 2018
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 391:219-229. 2018
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 377:1319-1330. 2017
- PREDICTORS OF COGNITIVE DECLINE AFTER CARDIAC SURGERY: AN EVALUATION OF THE CABG OFF OR ON PUMP REVASCULARIZATION STUDY (CORONARY) COHORT. Canadian Journal of Cardiology. 33:S36-S36. 2017
- Impact of Killing in War: A Randomized, Controlled Pilot Trial. Journal of Clinical Psychology. 73:997-1012. 2017
- Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial. Canadian Journal of Cardiology. 33:1027-1035. 2017
- Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial. American Society of Nephrology. Clinical Journal. 12:965-973. 2017
- Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses. Canadian Journal of Cardiology. 32:1108-1116. 2016
- Global Survey of the Frequency of Atrial Fibrillation–Associated Stroke. Stroke. 47:2197-2202. 2016
- Numbers can save lives: Janice Pogue (1962–2016). Clinical Trials. 13:464-465. 2016
- Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry. International Journal of Stroke. 11:526-533. 2016
- Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis. 42:90-98. 2016
- Age disparity in diagnostic evaluation of stroke patients: Embolic Stroke of Undetermined Source Global Registry Project. European Stroke Journal. 1:130-138. 2016
- Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. Hepatology. 63:1957-1967. 2016
- Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine. 374:2009-2020. 2016
- Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. New England Journal of Medicine. 374:2032-2043. 2016
- Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine. 374:2021-2031. 2016
- Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Reviews. 39:709-716. 2016
- Rapid reversal of haematoma expansion associated with vitamin K antagonists. Lancet Neurology. 15:535-537. 2016
- Updated Meta-Analysis of Aspirin in Primary Prevention of Cardiovascular Disease. American Journal of Medicine. 129:e35-e36. 2016
- Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. Canadian Journal of Cardiology. 32:311-318. 2016
- Enhanced TRAP-induced platelet aggregation with dabigatran — Clinical perspective. Thrombosis Research. 138:61-62. 2016
- Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study. Scientific Reports. 6:18672. 2016
- Net benefit of ticagrelor in patients with chronic kidney disease. Nature Reviews Nephrology. 12:10-11. 2016
- Obesity Genes and Risk of Major Depressive Disorder in a Multiethnic Population. Journal of Clinical Psychiatry. 76:e1611-e1618. 2015
- Global Survey of the Diagnostic Evaluation and Management of Cryptogenic Ischemic Stroke. International Journal of Stroke. 10:1031-1036. 2015
- The Safety of Eplerenone in Hemodialysis Patients. American Society of Nephrology. Clinical Journal. 10:1602-1608. 2015
- Development and Evaluation of Self-Management and Task-Oriented Approach to Rehabilitation Training (START) in the Home: Case Report. Physical Therapy. 95:934-943. 2015
- Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin. BMJ Evidence-Based Medicine. 20:117-117. 2015
- Mechanical left atrial appendage closure was noninferior and superior to warfarin in atrial fibrillation. ACP journal club. 162:JC4-JC4. 2015
- A Follow-up Study to Monitor Adult Height Among Spanish Children with Growth Hormone Deficiency Who Received Biosimilar Human Recombinant Growth Hormone (Omnitrope®) During a Phase III Clinical Trial. Advances in Therapy. 32:148-156. 2015
- Does Lowering Blood Pressure With Antihypertensive Therapy Preserve Independence in Activities of Daily Living? A Systematic Review. American Journal of Hypertension. 28:273-279. 2015
- Management of bleeding with oral anticoagulants in patients with atrial fibrillation. Hamostaseologie. 35:351-357. 2015
- Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial. European Journal of Cancer. 50:3077-3088. 2014
- Prednisolone andMycobacterium indicus praniiin Tuberculous Pericarditis. New England Journal of Medicine. 371:1121-1130. 2014
- Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: An individual patient based meta-analysis of two controlled trials. Journal of Hepatology. 61:252-259. 2014
- The Mini‐Mental State Examination, Clinical Factors, and Motor Vehicle Crash Risk. Journal of The American Geriatrics Society. 62:1419-1426. 2014
- Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. European Heart Journal. 35:1743-1751. 2014
- Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia. 57:1325-1331. 2014
- Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. The Lancet Diabetes and Endocrinology. 2:562-572. 2014
- Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: A subanalysis of the ORIGIN trial. International Journal of Cardiology. 174:458-461. 2014
- The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Reviews. 37:1360-1366. 2014
- Myocardial Injury after Noncardiac Surgery. Anesthesiology. 120:564-578. 2014
- Does Task-Oriented Practice Improve Upper Extremity Motor Recovery after Stroke? A Systematic Review. ISRN Rehabilitation. 2014:1-10. 2014
- Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. European Heart Journal. 35:353-364. 2014
- Randomized Clinical Trials — Removing Unnecessary Obstacles. New England Journal of Medicine. 369:1061-1065. 2013
- Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events. Diabetes Reviews. 36:2466-2474. 2013
- Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk Multiethnic Population. Diabetes Reviews. 36:2836-2842. 2013
- Setting the record straight on TIDE: a lost opportunity for patients with diabetes. Diabetologia. 56:1884-1887. 2013
- Effects of n-3 fatty acids on long-term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. European Heart Journal. 34:1966-1966. 2013
- Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: A 2 × 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis. American Heart Journal. 165:109-115.e3. 2013
- n-3 Fatty Acids and Cardiovascular Outcomes in Dysglycemia. New England Journal of Medicine. 367:1761-1761. 2012
- n-3 fatty acids and cardiovascular outcomes in dysglycemia.. New England Journal of Medicine. 367:1760-1761. 2012
- n–3 Fatty Acids and Cardiovascular Outcomes in Dysglycemia. New England Journal of Medicine. 367:1760-1761. 2012
- Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. American Journal of Clinical Nutrition. 96:584-590. 2012
- Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. European Journal of Preventive Cardiology (EJPC). 19:755-764. 2012
- Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine. 367:319-328. 2012
- n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine. 367:309-318. 2012
- Cognitive impairment and risk of cardiovascular events and mortality. European Heart Journal. 33:1777-1786. 2012
- Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Annals of Oncology. 23:1780-1788. 2012
- Error in Viewpoint in: Statin Therapy for Healthy Men Identified as ‘Increased Risk,’. Journal of the American Medical Association (JAMA). 307:2590-2590. 2012
- Insulin resistance in patients with cirrhosis and portal hypertension. American Journal of Physiology - Gastrointestinal and Liver Physiology. 302:G1458-G1465. 2012
- Association Between Postoperative Troponin Levels and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. Journal of the American Medical Association (JAMA). 307:2295-2295. 2012
- Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CANADIAN MEDICAL ASSOCIATION JOURNAL. 184:E329-E336. 2012
- Randomised clinical trial: the safety and efficacy of long‐acting octreotide in patients with portal hypertension. Alimentary Pharmacology and Therapeutics. 35:904-912. 2012
- High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial. European Journal of Surgical Oncology. 38:110-117. 2012
- Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. Diabetologia. 55:36-45. 2012
- Management of Hot Flashes in Patients Who Have Breast Cancer With Venlafaxine and Clonidine: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Oncology. 29:3862-3868. 2011
- The Fluid Study Protocol: A Randomized Controlled Study on the Effects of Bioimpedance Analysis and Vitamin D on Left Ventricular Mass in Peritoneal Dialysis Patients. Advances in peritoneal dialysis. Conference on Peritoneal Dialysis. 31:529-536. 2011
- Constructing trials to show whether urodynamic studies are necessary in lower urinary tract dysfunction. Neurourology and Urodynamics. 30:735-740. 2011
- Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal. Diabetes Reviews. 34:1265-1269. 2011
- Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia. 54:487-495. 2011
- The Polypill in the Prevention of Cardiovascular Diseases. Circulation. 122:2078-2088. 2010
- A Specialized, Nurse-Run Titration Clinic: A Feasible Option for Optimizing β-Blockade in Non–Clinical Trial Patients. American Journal of Gastroenterology. 105:1917-1921. 2010
- Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes. Diabetologia. 53:1322-1330. 2010
- Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. Gut. 58:1144-1150. 2009
- Lipid lowering for primary prevention (vol 373, pg 1152, 2009). The Lancet. 374:28-28. 2009
- A Double-Blind Randomized Trial of Mood Stabilizer Augmentation Using Lamotrigine and Valproate for Patients With Schizophrenia Who Are Stabilized and Partially Responsive. Journal of Clinical Psychopharmacology. 29:267-271. 2009
- Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. Journal of the American College of Cardiology. 53:2028-2035. 2009
- Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial. Gastroenterology. 136:1651-1658. 2009
- Lipid lowering for primary prevention. The Lancet. 373:1152-1155. 2009
- Erratum. Clinical Trials. 5:283-283. 2008
- Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. Diabetes Reviews. 31:1007-1014. 2008
- Sensible guidelines for the conduct of large randomized trials. Clinical Trials. 5:38-39. 2008
- Specific barriers to the conduct of randomized trials. Clinical Trials. 5:40-48. 2008
- Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). American Heart Journal. 155:26.e1-26.e13. 2008
- Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. European Heart Journal. 28:1382-1388. 2007
- A randomized clinical trial of a targeted intervention to moderate alcohol use and alcohol-related problems in at-risk adolescents. Pharmacology Biochemistry and Behavior. 86:368-376. 2007
- Effect of Ramipril on the Incidence of Diabetes. New England Journal of Medicine. 356:522-524. 2007
- Effect of ramipril on the incidence of diabetes - Reply. New England Journal of Medicine. 356:523-524. 2007
- The authors reply [6]. New England Journal of Medicine. 356:523-524. 2007
- Rosiglitazone delays the development of diabetes mellitus (DREAM trial). Cleveland Clinic Journal of Medicine. 74:64-64. 2007
- Independent design and conduct of clinical trials. Clinical Trials. 3:503-507. 2006
- The DREAM trial – Authors' reply. The Lancet. 368:2050-2051. 2006
- Effect of Ramipril on the Incidence of Diabetes. New England Journal of Medicine. 355:1551-1562. 2006
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. The Lancet. 368:1096-1105. 2006
- Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: The Heart Outcomes Prevention Evaluation (HOPE)-2 trial. Canadian Journal of Cardiology. 22:47-53. 2006
- Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes. Circulation. 112:1339-1346. 2005
- Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer. Journal of the American Medical Association (JAMA). 293:1338-1338. 2005
- Effects of long-term supplementation on and cancer vitamin E cardiovascular events - A randomized controlled trial. Journal of the American Medical Association (JAMA). 293:1338-1347. 2005
- Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE Study. Clinical Nephrology. 63:181-187. 2005
- Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. American Heart Journal. 149:54-60. 2005
- The HOPE (Heart Outcomes Prevention Evaluation) Study and its Consequences. Scandinavian Journal of Clinical and Laboratory Investigation, Supplement. 65:143-156. 2005
- Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction. Circulation. 110:1413-1417. 2004
- Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia. 47:1519-1527. 2004
- Assessing Acute Middle Cerebral Artery Ischemic Stroke by Quantitative Electric Tomography. Clinical EEG and Neuroscience. 35:116-124. 2004
- Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction. Journal of the American College of Cardiology. 43:2200-2206. 2004
- Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE Study. Kidney International. 65:1375-1380. 2004
- Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. European Heart Journal. 25:17-24. 2004
- Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. European Journal of Cardiovascular Prevention and Rehabilitation. 10:420-428. 2003
- Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. European Journal of Preventive Cardiology (EJPC). 10:420-428. 2003
- Conundrum of the HOPE study: Authors' reply. The BMJ. 327:682-682. 2003
- Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 107:1284-1290. 2003
- Preventing stroke with ramipril---authors' reply. The BMJ. 326:52-52. 2003
- Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes. Diabetes Reviews. 25:1919-1927. 2002
- Effect of long-term therapy with ramipril in high-risk women. Journal of the American College of Cardiology. 40:693-702. 2002
- Ramipril and cardiovascular risk reduction - Response. Circulation. 105:A194-A195. 2002
- Urate levels as a predictor of cardiac deaths: causal relation or mere association?. European Heart Journal. 23:760-761. 2002
- A pill for every ill - Response. Circulation. 105:E82-E82. 2002
- Use of ramipril in preventing stroke: double blind randomised trial. The BMJ. 324:699-699. 2002
- TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: A randomized controlled trial. Hepatology. 35:385-392. 2002
- Effect of ramipril and vitamin E on atherosclerosis - Response. Circulation. 105:E5-E6. 2002
- Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. Journal of Hepatology. 35:712-718. 2001
- Ramipril and the Development of Diabetes. Journal of the American Medical Association (JAMA). 286:1882-1882. 2001
- Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril. Circulation. 104:1615-1621. 2001
- Effects of Ramipril on Coronary Events in High-Risk Persons. Circulation. 104:522-526. 2001
- Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial. ACP journal club. 134:629-629. 2001
- Effects of Ramipril and Vitamin E on Atherosclerosis. Circulation. 103:919-925. 2001
- Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. Survey of Anesthesiology. 44:342-342. 2000
- Multicenter Randomized Controlled Trial of Terlipressin Versus Sclerotherapy in the Treatment of Acute Variceal Bleeding: The TEST Study. Hepatology. 32:471-476. 2000
- Implications of the Heart Outcomes Prevention Evaluation (HOPE) for the treatment of patients at high cardiovascular risk; systolic versus diastolic pressure predictive value. Heart. 83. 2000
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. New England Journal of Medicine. 342:145-153. 2000
- Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients. New England Journal of Medicine. 342:154-160. 2000
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. The Lancet. 355:253-259. 2000
- Summary of Randomized Trials of Angiotensin Converting Enzyme Inhibitors. Clinical and Experimental Hypertension. 21:835-845. 1999
- Randomized controlled trial of sclerotherapy versus somatostatin infusion in the prevention of early rebleeding following acute variceal hemorrhage in patients with cirrhosis. Journal of Hepatology. 29:779-788. 1998
- The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators.. Canadian Journal of Cardiology. 14:1349-1357. 1998
- The study of health assessment and risk in ethnic groups (SHARE): Rationale and design. Canadian Journal of Cardiology. 14:1349-1357. 1998
- Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. Gastroenterology. 111:1291-1299. 1996
- Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study. Diabetes Reviews. 19:1225-1228. 1996
- Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.. Diabetes Care. 19:1225-1228. 1996
- Collaborative cardiovascular clinical trials in Canada. The Canadian Cardiovascular Collaboration.. Canadian Journal of Cardiology. 11:649-657. 1995
- COST-EFFECTIVENESS STUDIES - CAN BENEFIT BE SHOWN ONLY IN HIGH-RISK POPULATIONS. British Journal of Clinical Practice. 22-25. 1995
- Propranolol versus sclerotherapy in preventing variceal rebleeding: A randomized controlled trial. Gastroenterology. 105:1508-1514. 1993
- Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. Hepatology. 13:902-912. 1991
- Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology. 99:1401-1407. 1990
- Vasopressin/nitroglycerin infusion vs. esophageal tamponade in the treatment of acute variceal bleeding: A randomized controlled trial. Hepatology. 11:964-968. 1990
- Balloon tamponade vs. endoscopic sclerotherapy: In the management of active variceal hemorrhage. Hepatology. 11:898-899. 1990
- Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo-controlled clinical trial. Hepatology. 10:962-968. 1989
- Relative hyperphosphaturia in diabetic chronic renal failure: a protective factor of hyperparathyroidism.. Mineral and Electrolyte Metabolism. 13:311-315. 1987
- Low incidence of hyperparathyroidism in diabetic renal failure.. Nephrology Dialysis Transplantation. 21:902-908. 1985